| Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma MA Pule, B Savoldo, GD Myers, C Rossig, HV Russell, G Dotti, MH Huls, ... Nature medicine 14 (11), 1264-1270, 2008 | 1343 | 2008 |
| Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma CU Louis, B Savoldo, G Dotti, M Pule, E Yvon, GD Myers, C Rossig, ... Blood, The Journal of the American Society of Hematology 118 (23), 6050-6056, 2011 | 1292 | 2011 |
| CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients B Savoldo, CA Ramos, E Liu, MP Mims, MJ Keating, G Carrum, ... The Journal of clinical investigation 121 (5), 1822-1826, 2011 | 1220 | 2011 |
| Human epidermal growth factor receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the immunotherapy of HER2-positive sarcoma N Ahmed, VS Brawley, M Hegde, C Robertson, A Ghazi, C Gerken, E Liu, ... Journal of clinical oncology 33 (15), 1688, 2015 | 1007 | 2015 |
| Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study CRY Cruz, KP Micklethwaite, B Savoldo, CA Ramos, S Lam, S Ku, ... Blood, The Journal of the American Society of Hematology 122 (17), 2965-2973, 2013 | 585 | 2013 |
| CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma A Heczey, CU Louis, B Savoldo, O Dakhova, A Durett, B Grilley, H Liu, ... Molecular therapy 25 (9), 2214-2224, 2017 | 451 | 2017 |
| Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes CA Ramos, B Ballard, H Zhang, O Dakhova, AP Gee, Z Mei, M Bilgi, ... The Journal of clinical investigation 127 (9), 3462-3471, 2017 | 371 | 2017 |
| Clinical responses with T lymphocytes targeting malignancy-associated κ light chains CA Ramos, B Savoldo, V Torrano, B Ballard, H Zhang, O Dakhova, E Liu, ... The Journal of clinical investigation 126 (7), 2588-2596, 2016 | 287 | 2016 |
| Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications N Lapteva, AG Durett, J Sun, LA Rollins, LL Huye, J Fang, V Dandekar, ... Cytotherapy 14 (9), 1131-1143, 2012 | 251 | 2012 |
| In vivo fate and activity of second-versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin’s lymphomas CA Ramos, R Rouce, CS Robertson, A Reyna, N Narala, G Vyas, B Mehta, ... Molecular Therapy 26 (12), 2727-2737, 2018 | 230 | 2018 |
| Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System PJ Hanley, Z Mei, AG Durett, M da Graca Cabreira-Harrison, M Klis, W Li, ... Cytotherapy 16 (8), 1048-1058, 2014 | 154 | 2014 |
| Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia M Boyiadzis, M Agha, RL Redner, A Sehgal, A Im, JZ Hou, R Farah, ... Cytotherapy 19 (10), 1225-1232, 2017 | 151 | 2017 |
| Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma RF Rousseau, AE Haight, C Hirschmann-Jax, ES Yvon, DR Rill, Z Mei, ... Blood, The Journal of the American Society of Hematology 101 (5), 1718-1726, 2003 | 136 | 2003 |
| Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell … RF Rousseau, E Biagi, A Dutour, ES Yvon, MP Brown, T Lin, Z Mei, ... Blood 107 (4), 1332-1341, 2006 | 95 | 2006 |
| Manufacturing mesenchymal stromal cells for phase I clinical trials PJ Hanley, Z Mei, M da Graca Cabreira-Hansen, M Klis, W Li, Y Zhao, ... Cytotherapy 15 (4), 416-422, 2013 | 77 | 2013 |
| Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes S Takahashi, RF Rousseau, P Yotnda, Z Mei, G Dotti, D Rill, R Hurwitz, ... Human gene therapy 12 (6), 659-670, 2001 | 74 | 2001 |
| Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin HV Russell, D Strother, Z Mei, D Rill, E Popek, E Biagi, E Yvon, M Brenner, ... Journal of immunotherapy 30 (2), 227-233, 2007 | 50 | 2007 |
| A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma HV Russell, D Strother, Z Mei, D Rill, E Popek, E Biagi, E Yvon, M Brenner, ... Journal of immunotherapy 31 (9), 812-819, 2008 | 40 | 2008 |
| Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma S Takahashi, P Yotnda, RF Rousseau, Z Mei, S Smith, D Rill, A Younes, ... Cancer gene therapy 8 (5), 378-387, 2001 | 38 | 2001 |
| T cell-activating mesenchymal stem cells as a biotherapeutic for HCC A Szoor, A Vaidya, MP Velasquez, Z Mei, DL Galvan, D Torres, A Gee, ... Molecular Therapy-Oncolytics 6, 69-79, 2017 | 34 | 2017 |
